Search

Author/Creator Finneran, Laura

1. Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Issue 11 (November 2020)

Authors:
Guo, Christina; Chénard-Poirier, Maxime; Roda, Desamparados; de Miguel, Maria; Harris, Samuel J; Candilejo, Irene Moreno; Sriskandarajah, Priya; Xu, Wen; Scaranti, Mariana; Constantinidou, Anastasia; King, Jenny; Parmar, Mona; Turner, Alison J; Carreira, Suzanne; Riisnaes, Ruth; Finneran, Laura; ...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 11(2020)
Page Start:
1478
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P-59 Results of DARS: a randomised phase III trial of dysphagia-optimised intensity modulated radiotherapy (DO-IMRT) versus standard IMRT (S-IMRT) in oropharyngeal (OPC) and hypopharyngeal (HPC) cancer. (July 2021)

Authors:
Nutting, Chris; Rooney, Keith; Foran, Bernie; Pettit, Laura; Beasley, Matthew; Finneran, Laura; Roe, Justin; Tyler, Justine; Petkar, Imran; Bhide, Shree; Frogley, Robert; Sydenham, Mark; Emson, Marie; Hall, Emma
Journal:
Oral oncology
Issue:
Volume 118(2021)Supplement
Page Start:
10
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search